期刊文献+

国产与进口氟康唑胶囊在健康人体的生物等效性研究 被引量:4

Study on bioequivalence of domestic and imported fluconazole capsules in healthy volunteers
暂未订购
导出
摘要 目的:研究氟康唑胶囊受试制剂(国产)和参比制剂(进口)在20例男性健康志愿者体内的药动学和相对生物利用度,并进行生物等效性评价。方法:采用双周期两制剂随机交叉试验法,单剂量口服150mg两种氟康唑胶囊,两次试验周期之间的清洗期为两周,采用HPLC法测定血浆中氟康唑浓度。结果:受试制剂和参比制剂的t1/2分别为(31.09±5.49)和(32.57±6.33)h;tmax分别为(1.05±0.63)和(1.54±1.14)h;cmax分别为(3.90±0.43)和(3.73±0.67)μg/ml;AUC0~120分别为(128.39±15.74)和(127.30±25.64)μg.h.ml-1;AUC0~∞分别为(139.02±18.12)和(138.48±29.90)μg.h.ml-1。受试制剂和参比制剂的主要药动学参数均无显著差异(P>0.05)。受试制剂的相对生物利用度为(102.25±9.29)%。结论:受试制剂和参比制剂具有生物等效性。 Objective: To evaluate the pharmacokinetics and relative bioavailability of domestic and imported fluconazole capsules in 20 healthy male volunteers. Methods;A single oral dose of 150 mg test(domestic) and reference(imported) flucon- azole preparations were given respectively to the volunteers according to randomized two-way crossover study design. The wash- out period was two weeks. The plasma concentration of fluconazole was determined by HPLC method. Results: The main phar- macokinetic parameters of the test and reference preparations were as follows: t;/2 (31.09±5.49) and (32.57±6.33) h; t (1.05±0.63) and (1.54;1.14) h;cmax(3. 90±0. 43) and (3.73±0.67) btg/ml;AUC0_120 (128.39±15.74) and (127.30±25.64) μg. h. ml 1;AUC0;(139.02±18.12) and (138.48±29.90)μg. h. ml l,respectively. There were no significant differences in main pharmacokinetic parameters between the test and reference preparations (P ; 0. 05 ). The relative bioavailability of the test preparation was (102.25±9.29);. Conclusion:The results of statistical analysis showed that the two formulations were bioequivalent.
出处 《药学服务与研究》 CAS CSCD 2013年第4期288-290,共3页 Pharmaceutical Care and Research
关键词 氟康唑 胶囊 生物利用度 药代动力学 色谱法 高效液相 fluconazole capsule bioavailability pharmacokinetics chromatography, high performance liquid
  • 相关文献

参考文献4

二级参考文献15

共引文献67

同被引文献14

引证文献4

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部